Literature DB >> 210669

Effect of immunization on the development of latent ganglionic infection in mice challenged intravaginally with herpes simplex virus types 1 and 2.

L V Asher, M A Walz, A L Notkins.   

Abstract

Immunization of BALB/c mice with virulent and avirulent strains of HSV-1 resulted in high levels of neutralizing antibody and protected against both the lethal effect of the virus and the development of a latent ganglionic infection when animals were challenged by the intravaginal route. In animals immunized with avirulent strain of HSV-2 and challenged with a high virulent strain of HSV-2, substantial protection against death was observed despite low levels of neutralizing antibody. Nineteen per cent of the survivors, however, developed a latent ganglionic infection. Relatively little protection was observed in mice immunized with HSV-1 and challenged with HSV-2.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 210669     DOI: 10.1016/0002-9378(78)90248-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Effective vaccination against long-term gammaherpesvirus latency.

Authors:  Scott A Tibbetts; J Scott McClellan; Shivaprakash Gangappa; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine.

Authors:  G R Skinner; C G Fink; M Cowan; A Buchan; A Fuller; C E Hartley; J Durham; C Wiblin; J Melling
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.

Authors:  H J Zweerink; D Martinez; R J Lynch; L W Stanton
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

4.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

5.  Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

6.  Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine.

Authors:  R J Klein; A E Friedman-Kien; E DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

7.  The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks.

Authors:  J A Lekstrom-Himes; L Pesnicak; S E Straus
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.

Authors:  G R Skinner; A Buchan; C E Hartley; S P Turner; D R Williams
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

9.  Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.

Authors:  Joshua J Geltz; Edward Gershburg; William P Halford
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.

Authors:  G R Skinner; D R Williams; A W Moles; A Sargent
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.